EQL PHARMA AB (7JK) — Tangible Net Worth Ratio
EQL PHARMA AB (7JK) has a Tangible Net Worth Ratio of -65.2% as of March 2026. This metric is calculated by deducting intangible assets (€441.11 Million) from net assets (€267.06 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore EQL PHARMA AB annual equity growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
EQL PHARMA AB Tangible Net Worth Ratio (2022–2026)
This chart shows how EQL PHARMA AB's Tangible Net Worth Ratio has changed across 5 annual periods from 2022 to 2026. As of March 2026, the ratio stands at -65.2%, reflecting net assets of €267.06 Million with intangible assets of €441.11 Million EUR. For live market cap and overall valuation, see EQL PHARMA AB market cap and net worth.
Annual Tangible Net Worth Ratio for EQL PHARMA AB (2022–2026)
The table below presents the year-by-year Tangible Net Worth Ratio for EQL PHARMA AB from 2022 to 2026, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore 7JK capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2026 | -65.2% | €267.06 Million | €441.11 Million | €850.89 Million | ▲ +16.8 pp |
| 2025 | -82.0% | €221.03 Million | €402.25 Million | €808.82 Million | ▼ -84.5 pp |
| 2024 | 2.5% | €177.73 Million | €173.31 Million | €373.76 Million | ▼ -23.0 pp |
| 2023 | 25.5% | €154.75 Million | €115.32 Million | €285.70 Million | ▲ +14.7 pp |
| 2022 | 10.8% | €123.63 Million | €110.24 Million | €237.89 Million | — |